相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Photoswitchable Serotonins for Optical Control of the 5-HT2A Receptor
Johannes Morstein et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2022)
Residency time of agonists does not affect the stability of GPCR-arrestin complexes
Nadja Moesslein et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease
Xudong Cao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease
Haoran Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity
Limin Su et al.
FEBS OPEN BIO (2022)
Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
J. L. Woodhead et al.
PHARMACEUTICAL RESEARCH (2020)
Revisit ligand-receptor interaction at the human vasopressin V 2 receptor: A kinetic perspective
Chunji Liu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Photoswitchable Antagonists for a Precise Spatiotemporal Control of β2-Adrenoceptors
Anna Duran-Corbera et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Photoswitchable Agonist for the Histamine H3 Receptor, a Prototypic Family A G-Protein-Coupled Receptor
Niels J. Hauwert et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Long residence time adenosine A1 receptor agonists produce sustained wash- resistant antilipolytic effect in rat adipocytes
Yi Yun et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways
Kin Sing Stephen Lee et al.
ACS CENTRAL SCIENCE (2019)
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
Bart J. Kramers et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Photoswitching the Efficacy of a Small-Molecule Ligand for a Peptidergic GPCR: from Antagonism to Agonism
Xavier Gomez-Santacana et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist
Jaume Taura et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Manipulating midbrain dopamine neurons and reward-related behaviors with light-controllable nicotinic acetylcholine receptors
Romain Durand-de Cuttoli et al.
ELIFE (2018)
Polycystic kidney disease
Carsten Bergmann et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics
J. Daniel Hothersall et al.
MOLECULAR PHARMACOLOGY (2017)
A Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy
Luca Agnetta et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Red-Shifting Azobenzene Photoswitches for in Vivo Use
Mingxin Dong et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins et al.
DRUG SAFETY (2015)
Translating slow-binding inhibition kinetics into cellular and in vivo effects
Grant K. Walkup et al.
NATURE CHEMICAL BIOLOGY (2015)
Drug-Target Residence Time-A Case for G Protein-Coupled Receptors
Dong Guo et al.
MEDICINAL RESEARCH REVIEWS (2014)
Photoswitching of ortho-Substituted Azonium Ions by Red Light in Whole Blood
Subhas Samanta et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
Anthony L. Gotter et al.
BMC NEUROSCIENCE (2013)
Dual-Point Competition Association Assay: A Fast and High-Throughput Kinetic Screening Method for Assessing Ligand-Receptor Binding Kinetics
Dong Guo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis
Vinita Takiar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time
Georges Vauquelin
EXPERT OPINION ON DRUG DISCOVERY (2010)
Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1
Sekiya Shibazaki et al.
HUMAN MOLECULAR GENETICS (2008)
Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney
Robert A. Fenton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor
Mark R. Dowling et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Pyridobenzodiazepines:: A novel class of orally active, vasopressin V2 receptor selective agonists
AA Failli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
分享论文
